VYNE Therapeutics Inc.
NCM: VYNELive Quote
📈 ZcoreAI Score
Our AI model analyzes VYNE Therapeutics Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get VYNE Z-Score →About VYNE Therapeutics Inc.
Healthcare
Biotechnology
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
📊 Fundamental Analysis
VYNE Therapeutics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 54.8% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -67.0%, which indicates that capital utilization is currently under pressure.
At a current price of $0.61, VYNE currently trades near the bottom of its 52-week range (19%), indicating potential value or weakness (Range: $0.28 - $1.99).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$20.33M
Trailing P/E
--
Forward P/E
-0.37
Beta (5Y)
1.95
52W High
$1.99
52W Low
$0.28
Avg Volume
303K
Day High
Day Low